Argiris Symeonidis

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Luca Malcovati, Eva Hellström‐Lindberg, David Bowen et al. · Blood · 2013 · 667 citations · Full text

Medicine, Hematology, Oncology +13

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 327 citations

Medicine, Hematology, Oncology +14

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

Meletios Α. Dimopoulos, Athanasios K. Anagnostopoulos, Marie‐Christine Kyrtsonis et al. · Journal of Clinical Oncology · 2007 · 277 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +15

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi et al. · The Lancet Oncology · 2016 · 236 citations

Life Sciences, Immunology, Pharmacotherapy +12

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

Efstathios Kastritis, Konstantinos Zervas, Argiris Symeonidis et al. · Leukemia · 2009 · 187 citations

Medicine, Hematology, Oncology +17